CervoMed to Participate in the BIO CEO and Investor Conference
February 21, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
February 12, 2024 08:00 ET
|
CervoMed Inc.
-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b...
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
February 07, 2024 08:30 ET
|
CervoMed Inc.
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating...
CervoMed to Participate in the Emerging Growth Conference 67
February 05, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
CervoMed to Participate in the Emerging Growth Conference 66
January 05, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...